Giraudo Bryan — SEC insider filings
SEC reporting owner CIK 1740847. 29 insider filings on record with FilingPulse; latest filed 2026-08-26.
Transaction summary — filings shown
Covers all 29 filings on record, filed 2020-10-14 to 2026-08-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 6 filings — 421,869 shares, $406,551 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 7 legs across 4 filings — 81,772 shares, $6,073,943 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 60.
- Largest priced transaction: sale of 36,000 shares @ $100.14 ($3,605,040) in Protagonist Therapeutics, Inc, filed 2026-05-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | Director | 7 | — | 4 legs · 59,130 sh · $5,918,880 | 12 |
| Gossamer Bio, Inc. (GOSS) | COO/CFO | 22 | 6 legs · 421,869 sh · $406,551 | 3 legs · 22,642 sh · $155,063 | 48 |
Insider filings — Giraudo Bryan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-26 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 25 (derivative) @ $1,000.00 · Grant/award (A): 5,800,051 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Protagonist Therapeutics, Inc (PTGX) | Option exercise (M): 24,000 @ $6.45 · Option exercise (M): 12,000 @ $6.98 · Sale (S): 36,000 @ $100.14 · Sale (S): 12,000 @ $100.07 · Sale (S): 6,000 @ $100 · Sale (S): 5,130 @ $100 · +2 more | EDGAR |
| 2026-03-20 | 4 | Gossamer Bio, Inc. (GOSS) | Disposition to issuer (D): 693,750 (derivative) · Disposition to issuer (D): 638,000 (derivative) · Disposition to issuer (D): 543,750 (derivative) · Disposition to issuer (D): 181,250 (derivative) · Disposition to issuer (D): 211,500 (derivative) · Disposition to issuer (D): 211,500 (derivative) · +16 more | EDGAR |
| 2026-01-06 | 4 | Protagonist Therapeutics, Inc (PTGX) | Grant/award (A): 2,695 @ $0 · Grant/award (A): 3,762 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 115,750 @ $0 · Grant/award (A): 693,750 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 181,250 @ $0 | EDGAR |
| 2025-03-06 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 638,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Protagonist Therapeutics, Inc (PTGX) | Grant/award (A): 5,130 @ $0 · Grant/award (A): 6,584 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 100,000 @ $0.59 | EDGAR |
| 2024-03-28 | 4 | Gossamer Bio, Inc. (GOSS) | Sale (S): 6,430 @ $1.16 | EDGAR |
| 2024-01-04 | 4 | Protagonist Therapeutics, Inc (PTGX) | Grant/award (A): 25,700 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 543,750 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 181,250 (derivative) @ $0 | EDGAR |
| 2023-11-14 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 200,000 @ $0.56 | EDGAR |
| 2023-07-26 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 54,020 @ $1.82 · Grant/award (A): 13,505 (derivative) @ $0.12 | EDGAR |
| 2023-05-09 | 4 | Gossamer Bio, Inc. (GOSS) | Disposition to issuer (D): 145,000 (derivative) · Disposition to issuer (D): 71,500 (derivative) · Disposition to issuer (D): 90,000 (derivative) · Disposition to issuer (D): 150,000 (derivative) · Disposition to issuer (D): 265,000 (derivative) · Grant/award (A): 96,667 (derivative) · +4 more | EDGAR |
| 2023-04-05 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 55,000 @ $1.02 | EDGAR |
| 2023-03-22 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 50,000 @ $0.97 · Grant/award (A): 211,500 (derivative) @ $0 | EDGAR |
| 2023-01-18 | 4 | Protagonist Therapeutics, Inc (PTGX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 211,500 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 13,869 @ $7.21 | EDGAR |
| 2022-05-27 | 4 | Protagonist Therapeutics, Inc (PTGX) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-03-24 | 4 | Gossamer Bio, Inc. (GOSS) | Sale (S): 10,722 @ $8.91 | EDGAR |
| 2022-01-10 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 265,000 (derivative) @ $0 | EDGAR |
| 2021-09-20 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-05-28 | 4 | Protagonist Therapeutics, Inc (PTGX) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2021-03-25 | 4 | Gossamer Bio, Inc. (GOSS) | Sale (S): 5,490 @ $9.48 | EDGAR |
| 2021-03-01 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 45,000 @ $0 · Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2020-10-14 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 3,000 @ $10.01 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-13 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1740847 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs